The global biosensors for point-of-care diagnostics market is projected to grow from USD 16.8 billion in 2026 to USD 27.6 billion by 2033, representing a 4.0% compound annual growth rate. Demand is being supported by the need for rapid, accurate and cost-effective testing, rising chronic and infectious disease burdens, greater awareness of early diagnosis and the expansion of home-based healthcare. Point-of-care biosensors are used in glucose, HbA1c, cardiac marker, infectious disease, hormone, cancer marker, coagulation, fertility and pregnancy testing. Technology advances across electrochemical, optical, thermal and piezoelectric transducers are improving sensitivity, accuracy, reliability and application range, while smartphone compatibility, cloud connectivity, telemedicine and remote monitoring are extending use beyond conventional healthcare facilities. North America is the largest regional market, Europe remains a major market, and Asia-Pacific is expected to record rapid growth as healthcare spending and diagnostic infrastructure expand. The report identifies opportunities in wearable devices, portable systems, multiplexed testing, advanced materials, enhanced bioreceptors, digital analysis and strategic partnerships.